Venoms as a platform for human drugs: Translating toxins into therapeutics

Expert Opinion on Biological Therapy

Volumn 11, Issue 11, 2011, Pages 1469-1484

  King, Glenn F ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Biologic; Disulfide bond; Drug; Peptide; Protein; Therapeutic; Venom

Indexed keywords

ACV 1; ALFIMEPRASE; ANCROD; BAY 867548; BOMBESIN; CENDERITIDE; CGX 1051; CGX 1160; CHLOROTOXIN; COBROTOXIN; CONANTOKIN G; CONTULAKIN G; COVASE; DESMOTEPLASE; DISULFIDE; EXENDIN 4; FIBROLASE; HAEMPATCH; ITM 601; NATRIURETIC FACTOR; OMEGA CONOTOXIN CVID; OMEGA CONOTOXIN MVIIA; PEPTIDE DERIVATIVE; PROHANIN; PSEUDOTARIN C; Q 8008; SHK 192; SNAKE VENOM; TEXTILININ 1; THA 901; THA 902; THA 903; UNCLASSIFIED DRUG; VENOM; VICROSTATIN; XEN 2174; XIMELAGATRAN;

AGKISTRODON; ANNELID WORM; ARTHROPOD; CNIDARIA; DISULFIDE BOND; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG POTENCY; DRUG SPECIFICITY; DRUG STABILITY; ECHINODERM; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; KIDNEY CLEARANCE; MASS SPECTROMETRY; MOLECULARLY TARGETED THERAPY; MOLLUSC; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYLOGENY; POISONOUS ANIMAL; REVIEW; TRANSCRIPTOMICS; VERTEBRATE; WART VIRUS;

ANIMALS; BIOLOGICAL AGENTS; DISULFIDES; DRUG DISCOVERY; HUMANS; PEPTIDES; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; VENOMS;

ANIMALIA;

EID: 80053645532     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.621940     Document Type: Review

References (107)

1. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009;8:959-68
2. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 2011;10:428-38
3. David E, Tramontin T, Zemmel R. Pharmaceutical R&D: the road to positive returns. Nat Rev Drug Discov 2009;8:609-10
4. Ortholand JY, Ganesan A. Natural products and combinatorial chemistry: back to the future. Curr Opin Chem Biol 2004;8:271-80 (Pubitemid 38759402)
5. Paterson I, Anderson EA. The renaissance of natural products as drug candidates. Science 2005;310:451-3 (Pubitemid 41507948)
6. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-77 (Pubitemid 46595760)
7. Clardy J, Walsh C. Lessons from natural molecules. Nature 2004;432:829-37 (Pubitemid 40037138)
8. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005;4:206-20 (Pubitemid 40372555)
9. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25 (Pubitemid 27046991)
10. Zhang MQ, Wilkinson B. Drug discovery beyond the 'rule-of-five'. Curr Opin Biotechnol 2007;18:478-88
11. Gomes A, Bhattacharjee P, Mishra R, et al. Anticancer potential of animal venoms and toxins. Indian J Exp Biol 2010;48:93-103
12. Meng Z, Yang P, Shen Y, et al. Pilot study of Huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer 2009;115:5309-18
13. Machkour-M'Rabet S, Henaut Y, Winterton P, et al. A case of zootherapy with the tarantula Brachypelma vagans Ausserer, 1875 in traditional medicine of the Chol Mayan ethnic group in Mexico. J Ethnobiol Ethnomed 2011;7:12
14. Reid PF. Alpha-cobratoxin as a possible therapy for multiple sclerosis: a review of the literature leading to its development for this application. Crit Rev Immunol 2007;27:291-302
15. Cushman DW, Ondetti MA. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 1991;17:589-92
16. Opie LH, Kowolik H. The discovery of captopril: from large animals to small molecules. Cardiovasc Res 1995;30:18-25
17. Vetter I, Davis JL, Rash LD, et al. Venomics: a new paradigm for natural products-based drug discovery. Amino Acids 2011;40:15-28
18. Fry BG, Roelants K, Champagne DE, et al. The toxicogenomic multiverse: convergent recruitment of proteins into animal venoms. Annu Rev Genomics Hum Genet 2009;10:483-511
19. Lewis RJ, Garcia ML. Therapeutic potential of venom peptides. Nat Rev Drug Discov 2003;2:790-802 (Pubitemid 37361811)
20. Mellor IR, Usherwood PN. Targeting ionotropic receptors with polyamine-containing toxins. Toxicon 2004;43:493-508 (Pubitemid 38520192)
21. Schroeder FC, Taggi AE, Gronquist M, et al. NMR-spectroscopic screening of spider venom reveals sulfated nucleosides as major components for the brown recluse and related species. Proc Natl Acad Sci USA 2008;105:14283-7
22. Escoubas P, Quinton L, Nicholson GM. Venomics: unravelling the complexity of animal venoms with mass spectrometry. J Mass Spectrom Rev 2008;43:279-95 (Pubitemid 351373929)
23. Escoubas P, King GF. Venomics as a drug discovery platform. Expert Rev Proteomics 2009;6:221-4
24. Vassilevski AA, Kozlov SA, Grishin EV. Molecular diversity of spider venom. Biochemistry (Mosc) 2009;74:1505-34
25. Olivera BM, Hillyard DR, Marsh M, et al. Combinatorial peptide libraries in drug design: lessons from venomous cone snails. Trends Biotechnol 1995;13:422-6
26. Sollod BL, Wilson D, Zhaxybayeva O, et al. Were arachnids the first to use combinatorial peptide libraries? Peptides 2005;26:131-9 (Pubitemid 40038886)
27. Fry BG. From genome to "venome": molecular origin and evolution of the snake venom proteome inferred from phylogenetic analysis of toxin sequences and related body proteins. Genome Res 2005;15:403-20 (Pubitemid 40467782)
28. Koh CY, Kini RM. From snake venom toxins to therapeutics-cardiovascular examples. Toxicon 2011;published online 27 March 2011; doi:10.1016/j.toxicon. 2011.03.017.
29. Fox JW, Serrano SMT. Approaching the golden age of natural product pharmaceuticals from venom libraries: an overview of toxins and toxin-derivatives currently involved in therapeutic or diagnostic applications. Curr Pharm Des 2007;13:2927-34 (Pubitemid 351545895)
30. Escoubas P, Sollod BL, King GF. Venom landscapes: mining the complexity of spider venoms via a combined cDNA and mass spectrometric approach. Toxicon 2006;47:650-63
31. Davis J, Jones A, Lewis RJ. Remarkable inter-and intra-species complexity of conotoxins revealed by LC/MS. Peptides 2009;30:1222-7
32. Miyashita M, Otsuki J, Hanai Y, et al. Characterization of peptide components in the venom of the scorpion Liocheles australasiae (Hemiscorpiidae). Toxicon 2007;50:428-37 (Pubitemid 47094885)
33. Smith JJ, Hill JM, Little MJ, et al. A unique scorpion toxin with a putative ancestral fold provides insight into evolution of the inhibitor cystine knot motif. Proc Natl Acad Sci USA 2011;108:10478-83
34. Possani LD, Becerril B, Delepierre M, et al. Scorpion toxins specific for Na +-channels. Eur J Biochem 1999;264:287-300
35. Han TS, Teichert RW, Olivera BM, et al. Conus venoms-a rich source of peptide-based therapeutics. Curr Pharm Des 2008;14:2462-79
36. Estrada G, Villegas E, Corzo G. Spider venoms: a rich source of acylpolyamines and peptides as new leads for CNS drugs. Nat Prod Rep 2007;24:145-61 (Pubitemid 46238593)
37. Platnick NI. Advances in spider taxonomy, 1992-1995: with redescriptions 1940-1980, New York Entomological Society & The American Museum of Natural History, New York, 1997. Available from: http://research. amnh.org/entomology/ spiders/catalog/
38. King GF, Escoubas P, Nicholson GM. Peptide toxins that selectively target insect NaV and CaV channels. Channels 2008;2:100-16
39. Janes RW. alpha-Conotoxins as selective probes for nicotinic acetylcholine receptor subclasses. Curr Opin Pharmacol 2005;5:280-92 (Pubitemid 40674252)
40. Mari F, Tytgat J. Natural peptide toxins. In: Mander L, Liu H-W. editors. Comprehensive Natural Products Chemistry II: Chemistry and Biology. Elsevier; Oxford: 2010. p. 511-38
41. Mouhat S, Jouirou B, Mosbah A, et al. Diversity of folds in animal toxins acting on ion channels. Biochem J 2004;378:717-26 (Pubitemid 38406846)
42. Pallaghy PK, Nielsen KJ, Craik DJ, et al. A common structural motif incorporating a cystine knot and a triple-stranded beta-sheet in toxic and inhibitory polypeptides. Protein Sci 1994;3:1833-9 (Pubitemid 24356606)
43. King GF, Tedford HW, Maggio F. Structure and function of insecticidal neurotoxins from Australian funnel-web spiders. J Toxicol Toxin Rev 2002;21:359-89 (Pubitemid 35425080)
44. Saez NJ, Senff S, Jensen JE, et al. Spider-venom peptides as therapeutics. Toxins 2010;2:2851-71
45. Daly NL, Craik DJ. Bioactive cystine knot proteins. Curr Opin Chem Biol 2011;15:362-8
46. Pimenta AM, De Lima ME. Small peptides, big world: biotechnological potential in neglected bioactive peptides from arthropod venoms. J Pept Sci 2005;11:670-6 (Pubitemid 41684253)
47. Favreau P, Menin L, Michalet S, et al. Mass spectrometry strategies for venom mapping and peptide sequencing from crude venoms: case applications with single arthropod specimen. Toxicon 2006;47:676-87 (Pubitemid 44308190)
48. King GF, Gentz MC, Escoubas P, et al. A rational nomenclature for naming peptide toxins from spiders and other venomous animals. Toxicon 2008;52:264-76
49. Liang S. Proteome and peptidome profiling of spider venoms. Expert Rev Proteomics 2008;5:731-46
50. Tedford HW, Sollod BL, Maggio F, et al. Australian funnel-web spiders: master insecticide chemists. Toxicon 2004;43:601-18 (Pubitemid 38520199)
51. Smith HS, Deer TR, Staats PS, et al. Intrathecal drug delivery. Pain Physician 2008;11:S89-S104 (Pubitemid 351682080)
52. Garber K. Peptide leads new class of chronic pain drugs. Nat Biotechnol 2005;23:399 (Pubitemid 41724906)
53. Malone J, Trautmann M, Wilhelm K, et al. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2009;18:359-67
54. Weintraub B. Victoza and Taspoglutide threaten Byetta franchise: updating diabetes revenue forecasts. inThought™ Research, Wolters Kluwer Pharma Solutions, 2010. Avaiable from http://www.in-thought.com/resources/Byetta% 20Trends-Feb 10.pdf [Last accessed 8 September 2011]
55. Thayer AM. Improving peptides. Chem Eng News 2011;89:13-20
56. Dimond PF. Could stapling revive peptide therapeutics? Genet Eng Biotech News 2010;September 20. Available from: http://www.genengnews.com/analysis-and- insight/could-stapling-revive-peptide-therapeutics/77899339/[Last accessed 8 September 2011]
57. Mukherjee AK, Sollod BL, Wikel SK, et al. Orally active acaricidal peptide toxins from spider venom. Toxicon 2006;47:182-7 (Pubitemid 43143227)
58. Khan SA, Zafar Y, Briddon RW, et al. Spider venom toxin protects plants from insect attack. Transgenic Res 2006;15:349-57 (Pubitemid 43901493)
59. Fletcher JI, Smith R, O'Donoghue SI, et al. The structure of a novel insecticidal neurotoxin, omega-atracotoxin-HV1, from the venom of an Australian funnel web spider. Nat Struct Biol 1997;4:559-66
60. Johnson JH, Bloomquist JR, Krapcho KJ, et al. Novel insecticidal peptides from Tegenaria agrestis spider venom may have a direct effect on the insect central nervous system. Arch Insect Biochem Physiol 1998;38:19-31 (Pubitemid 128681040)
61. Bloomquist JR. Mode of action of atracotoxin at central and peripheral synapses of insects. Invert Neurosci 2003;5:45-50 (Pubitemid 38049328)
62. Mamelak AN, Jacoby DB. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv 2007;4:175-86 (Pubitemid 46389915)
63. Aroui S, Ram N, Appaix F, et al. Maurocalcine as a non toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB. Pharm Res 2009;26:836-45
64. Clark RJ, Jensen J, Nevin ST, et al. The engineering of an orally active conotoxin for the treatment of neuropathic pain. Angew Chem Int Ed 2010;49:6545-8
65. Satkunanathan N, Livett B, Gayler K, et al. Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones. Brain Res 2005;1059:149-58 (Pubitemid 41457312)
66. Clark RJ, Akcan M, Kaas Q, et al. Cyclization of conotoxins to improve their biopharmaceutical properties. Toxicon 2010;published online 10 December 2010; doi:10.1016/j. toxicon.2010.12.003.
67. Akcan M, Stroud MR, Hansen SJ, et al. Chemical re-engineering of chlorotoxin improves bioconjugation properties for tumor imaging and targeted therapy. J Med Chem 2011;54:782-7
68. Armishaw CJ, Daly NL, Nevin ST, et al. alpha-Selenoconotoxins, a new class of potent alpha7 neuronal nicotinic receptor antagonists. J Biol Chem 2006;281:14136-43 (Pubitemid 43848341)
69. Muttenthaler M, Alewood PF. Selenopeptide chemistry. J Pept Sci 2008;14:1223-39
70. Mobli M, de Araujo AD, Lambert LK, et al. Direct visualization of disulfide bonds through diselenide proxies using 77Se NMR spectroscopy. Angew Chem Int Ed 2009;48:9312-14
71. Moroder L. Isosteric replacement of sulfur with other chalcogens in peptides and proteins. J Pept Sci 2005;11:187-214 (Pubitemid 40542352)
72. Gowd KH, Yarotskyy V, Elmslie KS, et al. Site-specific effects of diselenide bridges on the oxidative folding of a cystine knot peptide, omega-selenoconotoxin GVIA. Biochemistry 2010;49:2741-52
73. Norton RS. mu-Conotoxins as leads in the development of new analgesics. Molecules 2010;15:2825-44
74. Brust A, Palant E, Croker DE, et al. chi-Conopeptide pharmacophore development: toward a novel class of norepinephrine transporter inhibitor (Xen2174) for pain. J Med Chem 2009;52:6991-7002
75. Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 2006;30:351-67 (Pubitemid 43886897)
76. Sato AK, Viswanathan M, Kent RB, et al. Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 2006;17:638-42 (Pubitemid 44791908)
77. Antosova Z, Mackova M, Kral V, et al. Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol 2009;27:628-35
78. Vlieghe P, Lisowski V, Martinez J, et al. Synthetic therapeutic peptides: science and market. Drug Discov Today 2010;15:40-56
79. Anangi R, Chen C-Y, Cheng C-H, et al. Expression of snake venom toxins in Pichia pastoris. Toxin Rev 2007;26:169-87 (Pubitemid 46663895)
80. McIntyre JI. Use of spider-venom peptides for crop protection. 4th conference on Venoms to Drugs, Heron Island, Australia, 2011
81. Craik DJ, Adams DJ. Chemical modification of conotoxins to improve stability and activity. ACS Chem Biol 2007;2:457-68 (Pubitemid 350001542)
82. Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006;444:894-8 (Pubitemid 46024997)
83. Dove A. Breaching the barrier. Nat Biotechnol 2008;26:1213-15
84. O'Shea JC, Tcheng JE. Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa. Expert Opin Pharmacother 2002;3:1199-210
85. Menozzi A, Merlini PA, Ardissino D. Tirofiban in acute coronary syndromes. Expert Rev Cardiovasc Ther 2005;3:193-206 (Pubitemid 40424938)
86. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008;99:830-9 (Pubitemid 351705299)
87. Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 2004;11:3029-40 (Pubitemid 39545572)
88. Barnett A. Exenatide. Expert Opin Pharmacother 2007;8:2593-608 (Pubitemid 350031296)
89. Zhang L, Lu SH, Li L, et al. Batroxobin mobilizes circulating endothelial progenitor cells in patients with deep vein thrombosis. Clin Appl Thromb Hemost 2011;17:75-9
90. Hong H, Zhang Y, Sun J, et al. Positron emission tomography imaging of prostate cancer. Amino Acids 2010;39:11-27
91. Kolosov A, Goodchild CS, Cooke I. CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med 2010;11:262-73
92. Pennington MW, Beeton C, Galea CA, et al. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol Pharmacol 2009;75:762-73
93. Veiseh M, Gabikian P, Bahrami SB, et al. Tumor paint: a chlorotoxin: Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res 2007;67:6882-8 (Pubitemid 47105535)
94. Kesavan K, Ratliff J, Johnson EW, et al. Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J Biol Chem 2010;285:4366-74
95. Lee C, Chen HH, Lisy O, et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 2009;49:668-73
96. Receptopharm, Inc. Modified elapid venoms as stimulators of the immune reaction. US7758894; 2006
97. Wei JM, Zhu MW, Zhang ZT, et al. A multicenter, phase III trial of hemocoagulase Agkistrodon: hemostasis, coagulation, and safety in patients undergoing abdominal surgery. Chin Med J 2010;123:589-93
98. Medcalf RL. Desmoteplase: discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol 2011;published online 31 May 2011; doi: 10.1111/j.1476-5381.2011.01514.x.
99. National University of Singapore. Therapeutic molecules derived from snake venom. US6613745; 2000
100. Lipps BV. Synthetic peptide and uses for same. US7129334; 2002
101. Fry BG, Wickramaratana JC, Lemme S, et al. Novel natriuretic peptides from the venom of the inland taipan (Oxyuranus microlepidotus): isolation, chemical and biological characterisation. Biochem Biophys Res Commun 2005;327:1011-15 (Pubitemid 40137968)
102. Mazzuca M, Heurteaux C, Alloui A, et al. A tarantula peptide against pain via ASIC1a channels and opioid mechanisms. Nat Neurosci 2007;10:943-5 (Pubitemid 47185208)
103. Deval E, Noel J, Lay N, et al. ASIC3, a sensor of acidic and primary inflammatory pain. EMBO J 2008;27:3047-55
104. Earl ST, Masci PP, de Jersey J, et al. Drug development from Australian elapid snake venoms and the Venomics pipeline of candidates for haemostasis: Textilinin-1 (Q8008), Haempatch (Q8009) and CoVase (V0801). Toxicon 2010;published online 22 December 2010; doi:10.1016/j. toxicon.2010.12.010.
105. Minea RO, Helchowski CM, Zidovetzki SJ, et al. Vicrostatin-an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities. PLoS One 2010;5:e10929
106. Pu XC, Wong PT, Gopalakrishnakone P. A novel analgesic toxin (hannalgesin) from the venom of king cobra (Ophiophagus hannah). Toxicon 1995;33:1425-31
107. Levy DE, del Zoppo GJ, Demaerschalk BM, et al. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke 2009;40:3796-803